CEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health system, who have inflated the costs of their medicines.
NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.
The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum.
There is increasing recognition that skin clearance scores may not be enough to win over patients and doctors when it comes to the highly competitive market for psoriasis drugs, even though
Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZe
